ReviewCurrent opinion in lipidology1994
Atherosclerosis and arterial influx of lipoproteins.
Review in Current opinion in lipidology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01384058 (The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes
Who cites it
25 citing papers in PubMed, 124 citations in OpenAlex.
- Insights Into Causal Effects of Genetically Proxied Lipids and Lipid-Modifying Drug Targets on Cardiometabolic Diseases.Journal of the American Heart Association · 2025Article
- Lipoprotein(a) and Its Role in Peripheral Arterial Disease: A Narrative Review.Vascular health and risk management · 2025Review
- Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans.Journal of atherosclerosis and thrombosis · 2023Review
- The association of apolipoprotein B with chronic kidney disease in the Chinese population.Frontiers in endocrinology · 2023Article
- Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall.Journal of clinical medicine · 2022Review
- Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.Biomolecules · 2021Review
- Associations of Lipoprotein(a) With Coronary Atherosclerotic Burden and All-Cause Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention.Frontiers in cardiovascular medicine · 2021Article
- Parental history of coronary artery disease among adults with hypothyroidism: Case controlled study.Annals of medicine and surgery (2012) · 2020Article
- Lipoprotein (a): a historical appraisal.Journal of lipid research · 2017Review
- Investigating The Role of Novel Bioactive Compound fromIranian journal of pharmaceutical research : IJPR · 2017Article
- Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.Journal of lipid research · 2016Review
- The glycosylation-dependent interaction of perlecan core protein with LDL: implications for atherosclerosis.Journal of lipid research · 2015Article
- The role of the lymphatic system in cholesterol transport.Frontiers in pharmacology · 2015Review
- Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?Vascular health and risk management · 2015Review
- New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease: the Multi-ethnic Study of Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2014Article
- Demystifying the management of hypertriglyceridaemia.Nature reviews. Cardiology · 2013Review
- A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL₃+IDL]).Lipids in health and disease · 2013Article
- Review
- Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"Current controlled trials in cardiovascular medicine · 2001Article
- Genetics of atherosclerosis: the search for genes acting at the level of the vessel wall.Current atherosclerosis reports · 2000Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulation of atherogenic lipoproteins in the arterial intima is a key event in the development of atherosclerosis. The likelihood of increased lipoprotein accumulation in the intima increases with increasing influx: arterial influx of lipoproteins is increased by increased arterial wall permeability, increased lipoprotein concentration in plasma, and by high blood pressure. On entrance into the arterial intima, lipoproteins can either efflux as intact particles, be retained in the intima, or be degraded by intimal cells. Increased degradation as well as increased retention of lipoproteins in the intima have both been associated with increased development of atherosclerosis. Therefore, low rates of efflux of intact particles, as appears to be the case for large particles like VLDL, IDL, and possibly lipoprotein (a) could potentially promote atherosclerosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.